RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer
RenovoRx announced a peer-reviewed case series in Case Reports in Oncology describing two locally advanced pancreatic cancer patients treated with TAMP-mediated intra-arterial gemcitabine via RenovoCath. Both patients showed tumor treatment response, including CA 19-9 reductions and resolution of vascular narrowing, without major procedural complications, despite prior extensive treatment.
Key figures
- Drug Name
- IAG (intra-arterial gemcitabine via RenovoCath)
- Phase Of Trial
- Phase 3
- Q2 2026 revenue
- $909,000 record quarterly revenue
- Tigerpac enrollment
- full enrollment achieved August 2026
- Topline data expected
- second half of 2027
- Commercial revenue 2025
- $1.1 million RenovoCath sales
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.